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The use of inhaled corticosteroids in bronchial asthma has widened, but there is a lack of data on their effect 
on bone collagen synthesis and degradation. This paper reports the effect of three dose levels (200, 1000 and 
2000 ,ug day ~ r, 3 weeks each) of inhaled beclomethasone on specific characteristics of bone collagen 
metabolism in seven postmenopausal women with new asthma without any previous corticosteroid therapy. 
Serum aminoterminal (PINP) propeptide of human type I procollagen was seen, after an initial increase, to 
decrease significantly (from 42.2 to 35.5 pg 1 - r, P=O.OOl) with the higher doses of inhaled beclomethasone, 
but no statistical change was found in the carboxyterminal propeptide (PICP) or type I collagen crosslinked 
telopeptide (ICTP). This data shows that type I collagen synthesis may be disturbed when using high-dose 
inhaled corticosteroids. However, further studies are needed to assess the effects of inhaled beclomethasone on 
the ability of the osteoblasts to form bone matrix, and on the density of bone during a longer treatment period 
with inhaled corticosteroids. 
Introduction 
Systemic corticosteroids are effective in the treat- 
ment of asthma, but their long-term use is associated 
with bone loss (l-3). Inhaled glucocorticosteroids 
have been developed for the treatment of asthma in 
an attempt to minimize adverse systemic side-effects, 
especially on bone (4). Inhaled corticosteroids have 
been used for the last two decades and are now 
administered to more patients, at an earlier stage, 
and at greater doses than previously. However, 
clinicians and patients have lately raised the suspicion 
that inhaled corticosteroids may produce systemic 
side-effects of clinical note, although to a lesser extent 
than steroids administered systemically (5). Unfortu- 
nately, at present there is little data to evaluate the 
risk of osteoporosis on inhaled corticosteroids. 
Recent results have shown that high-dose inhaled 
beclomethasone decreases serum osteocalcin both in 
postmenopausal asthmatic women (6) and in healthy 
volunteers (7,8). Therefore, specific characteristics of 
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bone collagen metabolism were studied during three 
successive periods with three different dosages of 
inhaled beclomethasone among postmenopausal 
asthmatic women. In the present study, three novel 
serum markers of bone turnover were used to assess 
the short-term effect of beclomethasone on bone 
formation and resorption, respectively. Serum car- 
boxyterminal (PICP) and aminoterminal (PINP) 
propeptides of human type I procollagen are markers 
of type I collagen synthesis (9). Type I collagen 
crosslinked telopeptide (ICTP) is a peptide derived 
from mature type I collagen fibres and is a marker of 
type I collagen degradation. 
Patients and Methods 
Seven non-smoking, co-operative, postmenopausal 
women (age range 55-66 years) with newly diagnosed 
bronchial asthma were included in the present study. 
They had no history of fractures nor any nutritional, 
metabolic, renal or bone disease, and none had 
previously received inhaled or systemic cortico- 
steroids for any indication. None of these patients 
were taking drugs affecting calcium or phosphate 
metabolism, and they had not received oestrogen 
or other hormone substitution. The diagnosis of 
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asthma was based on symptoms, verification of 
bronchial hyper-reactivity (PD,,PEF<2.9 mg) in the 
dosimeter-based metacholine inhalation challenge, 
and at least 15% circadian variation in the peak 
expiratory flow rate. 
Each subject was admitted to the inpatient 
department. They were given thorough training in 
the use of inhaled drugs and the spacer, and were 
taught to rinse the mouth and throat carefully after 
having administered the drug. The technique of using 
inhaled drugs was checked to be correct at every 
hospital visit. All patients were allowed, when 
needed, to use an inhaled &agonist, salbutamol, 
to control asthmatic symptoms. After 2 days of 
preparatory examinations, each patient started a 
low-collagen diet which was continued to the sixth 
day, on which blood samples were taken at 7.30 a.m. 
The study was designed to give successively 
increasing doses of inhaled steroid. The patients 
started regular beclomethasone treatment 
(Becotide@) by using a spacer (Volumati@). The 
initial dose was 0.1 mg twice daily for 3 weeks, after 
which they were admitted for re-examination. The 
patients had already followed a low-collagen diet at 
home for 2 days. The beclomethasone dose was 
increased to 0.5 mg twice daily and the measurements 
were repeated after 3 weeks. In the final phase, the 
patients used 1.0 mg beclomethasone twice daily for 3 
weeks. At every checkpoint, the patients reported 
their feeling of asthma control, performed flow 
volume spirometry (Jaeger Maesterlab, Germany), 
and circadian PEF variation was measured using an 
ordinary Wright PEF meter. 
Serum PICP, PINP and ICTP values were 
measured later by radioimmunoassay from the 
samples which had been frozen to - 70°C im- 
mediately. The radioimmunoassay of PICP was 
performed according the method described by 
Melkko et al. (10). By this method, the intra-assay 
coefficients of variation (CV) were constantly around 
3% and the inter-assay CV was close to 5%. 
The aminoterminal propeptide of human type I 
procollagen (PINP) was isolated from the cul- 
ture medium of MG-63 osteosarcoma cells (1 l), its 
purity was verified by sodium dodecyl sulphate- 
polyacrylamide gel electrophoresis, and a radioim- 
munoassay was established for it with polyclonal 
antibodies (12). All the samples were analysed in the 
same run. The intra-assay CV was 5%. The radio- 
immunoassay for ICTP was performed as described 
by Risteli et al. (13). The intra- and inter-assay CV 
were less than 6% and S%, respectively. Type I 
collagen crosslinked telopeptide was purified by two 
successive reverse-phase separations on HPLC, and 
its identity was verified by N-terminal amino acid 
sequencing. Polyclonal antibodies against the telo- 
peptide were produced in rabbits and the peptide was 
labelled with the chloramine-T-method. 
The study protocol was approved by the local 
Ethics Committee and every patient gave her 
informed consent. Repeated measures analyses of 
variance (ANOVA, Primer, McGraw-Hill, Inc.) was 
applied to the biochemical changes observed between 
the certain checkpoints. 
Results 
All patients reported increased control of asthma 
even on the lowest dose (0.2 mg) of inhaled beclo- 
methasone. Both FEV, (from 2.1 to 2.4 1, P=O.O35) 
and morning PEF (from 340 to 400 1 - ’ min, 
P=O.OlO) values increased from baseline during the 
first 3-week period. Serum PICP and PINP increased 
from the baseline value during the same period: PICP 
from 97 to 103pgl-’ (P=O.O15) and PINP from 
42.2 to 47.9,ug l- ’ (PrO.032) (Table 1). Thereafter, 
the concentration of both these serum markers 
decreased. When comparing the baseline value with 
that after the three successive periods with three 
different dosages (200, 1000 and 2OOOpg day- ‘, 3 
weeks each) of inhaled beclomethasone (Table l), the 
increase in PICP was not statistically significant 
(P=O.192) but the decrease in PINP was highly 
significant (P=O.OOl). No statistically significant 
increases or decreases were found in serum ICTP 
values during the periods with different dosages of 
inhaled beclomethasone (Table 1). 
Discussion 
Recent results have shown that high-dose inhaled 
beclomethasone decreases serum osteocalcin in post- 
menopausal, asthmatic women (6). This agrees with 
the recent findings in healthy volunteers both on 
inhaled (7,s) and oral corticosteroid treatment (7,14). 
The present data shows that inhaled beclomethasone 
is able to decrease serum PINP as well as serum 
osteocalcin. Interestingly, as in the case of serum 
osteocalcin (6) serum PICP and PINP also increased 
at the beginning of the inhaled beclomethasone 
therapy (0.2 mg daily dose). This may reflect a stimu- 
latory effect of low-dose corticosteroid treatment on 
collagen synthesis, or improved control of asthma, 
making, for example, increased mobility possible. 
Better control of asthma was reported by every 
patient from the beginning of the study and was, 
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Table I Effect of inhaled beclomethasone (200, 1000 and 
2OOOpg day-‘, 3 weeks each) on serum PICP (ug l-l), 
PINP @g 1~ ‘) and ICTP @g 1 - ‘) values (mean + SEM) in 
seven postmenopausal, asthmatic women (ANOVA) 
Patient 
PICP PINP ICTP 
Week &gl-‘) cug1-‘1 @gl-‘) 
- 
1 0 103 41.3 5.16 
3 109 44.9 3.39 
6 85 38.3 2.36 
9 108 44.7 2.49 
2 0 88 27.2 2.90 
3 94 28.4 6.06 
6 88 23.7 4.54 
9 84 20.6 4.51 
3 0 98 28.7 3.01 
3 113 36.7 3.02 
6 116 37.8 3.81 
9 113 31.0 3.09 
4 0 98 59.6 2.48 
3 103 65.0 2.06 
6 101 52.1 1.92 
9 109 54.0 3.04 
5 0 132 58.1 2.35 
3 133 64.1 2.07 
6 121 52.7 2.34 
9 116 39.9 3.98 
6 0 53 23.3 2.03 
3 56 29.9 2.36 
6 54 21.4 1.65 
9 42 18.9 1.74 
7 0 109 51.3 2-97 
3 113 66.1 2.89 
6 103 51.8 3.31 
9 100 39.1 2.98 
Mean 0 97 42.2 2.99 
SEM 9 5.8 0.39 
Mean 3 103 47.9 3.12 
SEM 9 6.4 0.53 
Mean 6 95 39.7 2.85 
SEM 9 5.0 0.40 
Mean 9 96 35.5 3.12 
SEM 10 4.8 0.35 
P by ANOVA 0.192 0.001 0.923 
Reference values: PICP 50-170,~g l- ’ for females and 
38&202pg l- ’ for males; PINP 17-79,~g 1~ 1 for females 
and 10-77pg 1-l for males; ICTP 1.6-4.6,~g l- I. PICP, 
carboxyterminal propeptide of type I collagen; PINP, ami- 
noterminal propeptide of type I collagen; ICTP, carboxy- 
terminal telopeptide of type I collagen. 
accordingly, seen as the increase of FEV, and PEF 
values. 
The value of osteocalcin as a marker of bone 
matrix formation is unclear, as fluctuations in 
circulating osteocalcin may only reflect changes in the 
equilibrium between bone matrix and blood (15). The 
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Fig. I Effect of inhaled beclomethasone (200, 1000 and 
2000 pug day I, 3 weeks each) on serum aminoterminal 
propeptide of human type I procollagen (PINP) @g l- ‘) 
values (mean * sEM) in seven postmenopausal women 
(ANOVA). 
reason for the discordant behaviour of PICP and 
PINP is not known. Both propeptides are cleared 
from the circulation via specific receptors on liver 
endothelial cells (16), and it is possible that gluco- 
corticoid treatment effects the function of the 
receptors differently. 
Inhaled beclomethasone has now been shown to 
decrease type I collagen synthesis, reflected as a 
decrease of serum PINP. The present results are in 
line with earlier short-term studies suggesting reduc- 
tion of bone formation with inhaled corticosteroids 
(8,17-19). However, these results should be inter- 
preted with care in deducing long-term changes in 
bone turnover during treatment with inhaled 
corticosteroids (20). Further studies are needed to 
assess the effects of inhaled beclomethasone on the 
ability of the osteoblasts to form bone matrix, and 
on the density of bone during a longer period of 
treatment with inhaled corticosteroid (21). 
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